Protocol tips
Upstream tips |
Protocol tips |
Downstream tips |
- XL10-Gold cells are resistant to tetracycline and chloramphenicol. If the mutagenized plasmid contains only the tetR or camR resistance marker, an alternative strain of competent cells must be used |
- Use only the Dpn I enzyme provided; do not substitute with an enzyme from another source. |
|
Upstream tips |
- XL10-Gold cells are resistant to tetracycline and chloramphenicol. If the mutagenized plasmid contains only the tetR or camR resistance marker, an alternative strain of competent cells must be used |
Protocol tips |
- Use only the Dpn I enzyme provided; do not substitute with an enzyme from another source. |
Publication protocol
Plasmid constructs
A 450-bp fragment of the uPAR promoter ( −402/+48 region) and the luciferase gene present in the pAd-TrackuPARLuc [3] were excised and cloned into a pGEM-T vector (puPARLuc). The reporter plasmid puPARLuc-NF-κBmut was generated by directed mutagenesis. The NF-kB binding site in the uPAR promoter (located at −45 bp of transcription initiation site) 5'-GGGAGGAGT-3' [13], was mutated to 5'-GGATCCAGT-3', using the QuikChange Multi Site-Directed Mutagenesis Kit (Agilent, CA USA), as recommended by the manufacturer and using the mutagenesis primer: 5'-ctctttcgcaaaacgtctggatccagtccctggggccacaaaac-3'. puPARE1A was generated by cloning the uPARE1A construct in a pGEM-T vector. The NF-κBmutation in the puPARE1A to generate puPARE1A-NF-κBmut was carried out by directed mutagenesis as described above. 3xκB-Luc reporter plasmid was previously described [31].
Full paper
Login or
join for free to view the full paper.
Reviews
QuikChange Multi Site-Directed Mutagenesis Kit from Agilent Technologies has not yet been reviewed for this experiment
We'd love it if you would be the first to write a review!
Discussion
Start your discussion
Share your thoughts or question with experts in your field
Start a discussion
Papers
Check out relevant papers found by Labettor's AI that are relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation BxPC-3 uPAR using QuikChange Multi Site-Directed Mutagenesis Kit from Agilent Technologies.
Paper title
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation
Manufacturer protocol
Download the product protocol from Agilent Technologies for QuikChange Multi Site-Directed Mutagenesis Kit below.
Download manufacturer protocol
Videos
Check out videos that might be relevant for performing Site Directed Mutagenesis (SDM) Human - Point mutation BxPC-3 uPAR using QuikChange Multi Site-Directed Mutagenesis Kit from Agilent Technologies. Please note that these videos are representative and steps or experiment specific processes must be kept in mind to expect desired results.
We haven't found any additional videos for this experiment / product combination yet.